{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T15:23:02Z","timestamp":1754148182045,"version":"3.41.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012729","name":"Case Western Reserve University School of Medicine | Clinical and Translational Science Collaborative of Cleveland, School of Medicine, Case Western Reserve University","doi-asserted-by":"publisher","award":["UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548"],"award-info":[{"award-number":["UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548","UL1TR002548"]}],"id":[{"id":"10.13039\/100012729","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)"],"award-info":[{"award-number":["P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)","P30EY025585(BA-A)"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background\/Objectives<\/jats:title>\n            <jats:p>Medication assisted weight loss for treatment of obesity has rapidly increased. The effect of this treatment with phentermine on diabetic retinopathy (DR) is underexplored.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects\/Methods<\/jats:title>\n            <jats:p>Retrospective cohort study. The U.S. Collaborative Network of the TriNetX platform was queried for patients diagnosed with overweight and obesity and prescription of phentermine. Patients were propensity score matched across baseline demographics and systemic risk factors at the time of medication initiation and compared to those diagnosed with overweight and obesity without usage of weight loss medications, identifying 26,611 patients per cohort after propensity score matching. Risk ratios (RR) of incident DR and related diagnoses or procedural codes found after the medication initiation date for pertinent disease worsening and treatment metrics were assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Phentermine usage was found to be associated with reduced future risk of a new diagnosis of DR with macular oedema (RR 0.462; (95% CI 0.372\u20130.573), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), mild non-proliferative diabetic retinopathy (NPDR) (RR 0.621 (0.508, 0.760), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), moderate NPDR (RR 0.567 (0.402, 0.799), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), severe NPDR (RR 0.477 (0.233, 0.981), <jats:italic>P<\/jats:italic>\u2009=\u20090.003), proliferative diabetic retinopathy (PDR) (RR 0.451 (0.323, 0.629), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), vitreous haemorrhage (RR 0.347 (0.200, 0.602), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), need for intravitreal anti-VEGF injection (RR: 0.530 (0.354, 0.793), <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The present analysis suggests that phentermine usage is associated with a decreased risk of diabetic macular oedema, NPDR, PDR, and worsening events.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41433-025-03818-x","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T13:50:48Z","timestamp":1746885048000},"page":"2183-2187","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lower incidence of diabetic retinopathy and worsening events after phentermine assisted weight loss across a large U.S. cohort"],"prefix":"10.1038","volume":"39","author":[{"given":"Madhukar","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia J.","family":"Abbass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew W.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Das","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi P.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0458-4181","authenticated-orcid":false,"given":"Katherine E.","family":"Talcott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"3818_CR1","doi-asserted-by":"publisher","first-page":"e184587","DOI":"10.1001\/jamanetworkopen.2018.4587","volume":"1","author":"H Xu","year":"2018","unstructured":"Xu H, Cupples LA, Stokes A, Liu CT. Association of obesity with mortality over 24 years of weight history: findings from the Framingham Heart Study. JAMA Netw Open. 2018;1:e184587. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4587.","journal-title":"JAMA Netw Open"},{"key":"3818_CR2","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1002\/oby.22581","volume":"27","author":"DR Saxon","year":"2019","unstructured":"Saxon DR, Iwamoto SJ, Mettenbrink CJ, McCormick E, Arterburn D, Daley MF, et al. Antiobesity medication use in 2.2 million adults across eight large health care organizations: 2009\u20132015. Obesity (Silver Spring). 2019;27:1975\u201381. https:\/\/doi.org\/10.1002\/oby.22581.","journal-title":"Obesity (Silver Spring)"},{"key":"3818_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","volume":"100","author":"CM Apovian","year":"2015","unstructured":"Apovian CM, Aronne LJ, Bessesen DH, McDonnell ME, Murad MH, Pagotto U, et al. Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342\u201362. https:\/\/doi.org\/10.1210\/jc.2014-3415.","journal-title":"J Clin Endocrinol Metab"},{"key":"3818_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.mcna.2017.08.006","volume":"102","author":"DH Ryan","year":"2018","unstructured":"Ryan DH, Kahan S. Guideline recommendations for obesity management. Med Clin North Am. 2018;102:49\u201363. https:\/\/doi.org\/10.1016\/j.mcna.2017.08.006.","journal-title":"Med Clin North Am"},{"key":"3818_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1210\/er.2017-00253","volume":"39","author":"GA Bray","year":"2018","unstructured":"Bray GA, Heisel WE, Afshin A, Jensen MD, Dietz WH, Long M, et al. The science of obesity management: an endocrine society scientific statement. Endocr Rev. 2018;39:79\u2013132. https:\/\/doi.org\/10.1210\/er.2017-00253.","journal-title":"Endocr Rev"},{"key":"3818_CR6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.metabol.2015.08.001","volume":"64","author":"D Patel","year":"2015","unstructured":"Patel D. Pharmacotherapy for the management of obesity. Metabolism. 2015;64:1376\u201385. https:\/\/doi.org\/10.1016\/j.metabol.2015.08.001.","journal-title":"Metabolism"},{"key":"3818_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1385\/endo:29:1:49","volume":"29","author":"DL Nelson","year":"2006","unstructured":"Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine. 2006;29:49\u201360. https:\/\/doi.org\/10.1385\/endo:29:1:49.","journal-title":"Endocrine"},{"key":"3818_CR8","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/oby.21244","volume":"24","author":"EA Thomas","year":"2016","unstructured":"Thomas EA, McNair B, Bechtell JL, Ferland A, Cornier MA, Eckel RH. Greater hunger and less restraint predict weight loss success with phentermine treatment. Obesity (Silver Spring). 2016;24:37\u201343. https:\/\/doi.org\/10.1002\/oby.21244.","journal-title":"Obesity (Silver Spring)"},{"key":"3818_CR9","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41366-021-01019-6","volume":"46","author":"G Calderon","year":"2022","unstructured":"Calderon G, Gonzalez-Izundegui D, Shan KL, Garcia-Valencia OA, Cifuentes L, Campos A, et al. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. Int J Obes (Lond). 2022;46:555\u201363. https:\/\/doi.org\/10.1038\/s41366-021-01019-6.","journal-title":"Int J Obes (Lond)"},{"key":"3818_CR10","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1093\/ajcn\/34.12.2763","volume":"34","author":"JR Arch","year":"1981","unstructured":"Arch JR. The contribution of increased thermogenesis to the effect of anorectic drugs on body composition in mice. Am J Clin Nutr. 1981;34:2763\u20139. https:\/\/doi.org\/10.1093\/ajcn\/34.12.2763.","journal-title":"Am J Clin Nutr"},{"key":"3818_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejphar.2005.02.044","volume":"513","author":"R Ferrer-Lorente","year":"2005","unstructured":"Ferrer-Lorente R, Cabot C, Fern\u00e1ndez-L\u00f3pez JA, Remesar X, Alemany M. Effects of oleoyl-estrone with dexfenfluramine, sibutramine or phentermine on overweight rats. Eur J Pharm. 2005;513:243\u20138. https:\/\/doi.org\/10.1016\/j.ejphar.2005.02.044.","journal-title":"Eur J Pharm"},{"key":"3818_CR12","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc16-2427","volume":"40","author":"P Hollander","year":"2017","unstructured":"Hollander P, Bays HE, Rosenstock J, Frustaci ME, Fung A, Vercruysse F, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40:632\u20139. https:\/\/doi.org\/10.2337\/dc16-2427.","journal-title":"Diabetes Care"},{"key":"3818_CR13","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, Winslow D, Odeh S, Gadde KM. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21:2163\u201371. https:\/\/doi.org\/10.1002\/oby.20584.","journal-title":"Obesity (Silver Spring)"},{"key":"3818_CR14","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1001\/archinte.161.15.1814","volume":"161","author":"G Glazer","year":"2001","unstructured":"Glazer G. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med. 2001;161:1814\u201324. https:\/\/doi.org\/10.1001\/archinte.161.15.1814.","journal-title":"Arch Intern Med"},{"key":"3818_CR15","unstructured":"Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People - PMC. Accessed July 28, 2023. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2687747\/."},{"key":"3818_CR16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1111\/j.1463-1326.2010.01242.x","volume":"12","author":"JG Kang","year":"2010","unstructured":"Kang JG, Park CY, Kang JH, Park YW, Park SW. Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity. Diabetes Obes Metab. 2010;12:876\u201382. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01242.x.","journal-title":"Diabetes Obes Metab"},{"key":"3818_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","volume":"377","author":"KM Gadde","year":"2011","unstructured":"Gadde KM, Allison DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341\u201352. https:\/\/doi.org\/10.1016\/S0140-6736(11)60205-5.","journal-title":"Lancet"},{"key":"3818_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/oby.2011.330","volume":"20","author":"DB Allison","year":"2012","unstructured":"Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, et al. Controlled-release phentermine\/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20:330\u201342. https:\/\/doi.org\/10.1038\/oby.2011.330.","journal-title":"Obesity (Silver Spring)"},{"key":"3818_CR19","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1530\/EC-21-0172","volume":"10","author":"GR Yang","year":"2021","unstructured":"Yang GR, Li D, Xie Z. Association of obesity with diabetic retinopathy in US adults with diabetes in a national survey. Endocrine Connect. 2021;10:725\u201330. https:\/\/doi.org\/10.1530\/EC-21-0172.","journal-title":"Endocrine Connect"},{"key":"3818_CR20","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ajo.2020.12.033","volume":"225","author":"CW Yu","year":"2021","unstructured":"Yu CW, Park LJ, Pinto A, Ma ON, Lee Y, Gupta R, et al. The impact of bariatric surgery on diabetic retinopathy: a systematic review and meta-analysis. American J Ophthalmol. 2021;225:117\u201327. https:\/\/doi.org\/10.1016\/j.ajo.2020.12.033.","journal-title":"American J Ophthalmol"},{"key":"3818_CR21","doi-asserted-by":"publisher","first-page":"e11807","DOI":"10.1097\/MD.0000000000011807","volume":"97","author":"W Zhu","year":"2018","unstructured":"Zhu W, Wu Y, Meng YF, Xing Q, Tao JJ, Lu J. Association of obesity and risk of diabetic retinopathy in diabetes patients. Medicine (Baltim). 2018;97:e11807 https:\/\/doi.org\/10.1097\/MD.0000000000011807.","journal-title":"Medicine (Baltim)"},{"key":"3818_CR22","doi-asserted-by":"publisher","first-page":"3309","DOI":"10.2337\/dc14-0930","volume":"37","author":"WT Garvey","year":"2014","unstructured":"Garvey WT, Ryan DH, Bohannon NJV, Kushner RF, Rueger M, Dvorak RV, et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014;37:3309\u201316. https:\/\/doi.org\/10.2337\/dc14-0930.","journal-title":"Diabetes Care"},{"key":"3818_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02608-3","volume":"22","author":"J Setareh","year":"2022","unstructured":"Setareh J, Hoseinzade G, Khoundabi B, Kamali M, Ebrahimi A, Fazlollahpour-Naghibi A, et al. Can the level of HbA1C predict diabetic retinopathy among type II diabetic patients?. BMC Ophthalmol. 2022;22:415. https:\/\/doi.org\/10.1186\/s12886-022-02608-3.","journal-title":"BMC Ophthalmol"},{"key":"3818_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","volume":"376","author":"F Ismail-Beigi","year":"2010","unstructured":"Ismail-Beigi F, Craven T, Banerji M, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycemia on microvascular complications of type 2 diabetes in ACCORD: a randomized trial. Lancet. 2010;376:419\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(10)60576-4.","journal-title":"Lancet"},{"key":"3818_CR25","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1016\/j.ophtha.2014.07.019","volume":"121","author":"EY Chew","year":"2014","unstructured":"Chew EY, Davis MD, Danis RP, Lovato JF, Perdue LH, Greven C, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014;121:2443\u201351. https:\/\/doi.org\/10.1016\/j.ophtha.2014.07.019.","journal-title":"Ophthalmology"},{"key":"3818_CR26","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.2337\/db13-1093","volume":"62","author":"DM Nathan","year":"2013","unstructured":"Nathan DM, Bayless M, Cleary P, Genuth S, Gubitosi-Klug R, Lachin JM, et al. Diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: advances and contributions. Diabetes. 2013;62:3976\u201386. https:\/\/doi.org\/10.2337\/db13-1093.","journal-title":"Diabetes"},{"key":"3818_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/dom.13538","volume":"21","author":"SC Bain","year":"2019","unstructured":"Bain SC, Klufas MA, Ho A, Matthews DR. Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: a review. Diabetes Obes Metab. 2019;21:454\u201366. https:\/\/doi.org\/10.1111\/dom.13538.","journal-title":"Diabetes Obes Metab"},{"key":"3818_CR28","unstructured":"FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. Published online 2021."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03818-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03818-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T13:54:56Z","timestamp":1752846896000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03818-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3818"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03818-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"type":"print","value":"0950-222X"},{"type":"electronic","value":"1476-5454"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KET reports Alimera (consultant), Apellis (consultant), Bausch and Lomb (consultant), Eyepoint (consultant), Genentech (consultant, speaker\u2019s bureau), Iveric Bio (speaker\u2019s bureau), Regeneron (research), Regenxbio (research), Zeiss (research). RPS reports personal fees from Eyepoint, Ocular Therapeutix, Genentech\/Roche, Alcon, Novartis, Regeneron, Asclepix, Gyroscope, Bausch and Lomb, Apellis. All other authors report no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}